BRIEF published on 04/07/2026 at 19:04, 7 months 14 days ago GenSight Biologics Reports Cash Status and Early Access Revenues Revenue Cash Position Gene Therapy GenSight Biologics Early Access Program
PRESS RELEASE published on 04/07/2026 at 18:59, 7 months 14 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 7 months 25 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
PRESS RELEASE published on 03/27/2026 at 07:30, 7 months 25 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 7 months 29 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
BRIEF published on 03/18/2026 at 10:20, 8 months 3 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
PRESS RELEASE published on 03/18/2026 at 10:15, 8 months 3 days ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 8 months 11 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 8 months 11 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 8 months 12 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
Published on 11/20/2026 at 15:00, 1 day 12 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 13 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 13 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 14 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 4 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 6 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 8 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 8 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 9 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 10 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 8 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 19 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing